Business Trends– category –
-
Rigetti Computing’s Stock Downturn and High Burn Rate Highlight Quantum Computing Commercialization Challenges
Kavout USA Overview Recent analyst downgrades and stock price declines for quantum computing firm Rigetti Computing (RGTI) underscore the lengthy and capital-intensive path to quantum computing commercialization. Despite an ambitious roa... -
Japanese Quantum Startup Yaqumo Secures Seed Extension Funding from U.S. VC Alumni Ventures, Marking First Investment in Japan
Yaqumo Japan Overview Japanese quantum computing startup Yaqumo has successfully closed a seed extension funding round from prominent U.S. venture capital firm Alumni Ventures. This investment marks Alumni Ventures' inaugural venture int... -
U.S. Government Prepares Major Quantum Investment; Fujitsu & RIKEN Target 10,000+ Physical Qubits by 2031
moomoo Community USA, Japan Overview The U.S. government plans significant investments in quantum computing, while Fujitsu, in collaboration with RIKEN, is developing a 256-qubit superconducting quantum computer. Their roadmap aims for 1... -
National Initiatives Propel Quantum Investment Boom: Global VC Funding Accelerates, Concentrating Half of Post-2025 Deals in Past 18 Months
Preqin Global Overview A recent Preqin report reveals a significant acceleration in quantum technology investment, with nearly half (48.2%) of global venture capital deals since early 2025 occurring in the last 18 months. This surge is p... -
Nkarta Develops Off-the-Shelf NK Cell Therapies NKX019 and NKX101 for Solid and Hematologic Malignancies, Balancing Scalability with Clinical Efficacy
Umbrex USA Overview Nkarta, a clinical-stage biotechnology company, specializes in off-the-shelf NK cell therapies derived from healthy donors, developing NKX019 for B-cell malignancies and NKX101 for Acute Myeloid Leukemia (AML) as its ... -
Miltenyi Biotec Builds Scalable Global T-Cell Manufacturing Platform Using Automated, Closed Systems
Bioprocess Online / Miltenyi Biotec Germany Overview Miltenyi Biotec is actively developing a scalable global T-cell manufacturing platform that leverages automated, closed systems. The strategy emphasizes integrating six critical produc... -
Engineered Allogeneic Treg Cell Therapy TRX103 Enters Phase 1/2a Clinical Trials for Crohn’s Disease and GvHD Prevention
Frontiers Global Overview The gene-edited allogeneic Treg cell therapy candidate TRX103, designed as a scalable, off-the-shelf application, has commenced Phase 1/2a clinical evaluation for Crohn's disease and Graft-versus-Host Disease (G... -
Cellbase Guide: Perfusion Culture Unlocks 10^9 Cells/mL, Revolutionizing Bioreactor Productivity
Cellbase フィンランド Overview Cellbase's new guide on bioreactor scale-up highlights perfusion culture as a critical technology for achieving unprecedented cell densities, often reaching 10^7–10^8 cells/mL and potentially up to 10^9 cel... -
FUJIFILM Completes £400M UK Teesside CDMO Expansion, Accelerating Bioprocess Innovation and Cell Product Diversification
Fujifilm Japan Overview FUJIFILM announced significant life sciences advancements at BIO 2026, notably completing a £400 million investment in its UK Teesside manufacturing facility, making it the largest single-use CDMO site in the coun... -
Advancing Cell Therapy Production: CCRM, OmniaBio, and Avectas Pioneer Automated Hub-and-Spoke Model for CAR-T, iPSC, and Lentiviral Vectors
PR Newswire (CCRM) Canada, アイルランド Overview CCRM and its CDMO subsidiary, OmniaBio, have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This strategic alliance ...
